AU2001261515A1 - Treatment of human papillomavirus (hpv)-infected cells - Google Patents

Treatment of human papillomavirus (hpv)-infected cells

Info

Publication number
AU2001261515A1
AU2001261515A1 AU2001261515A AU6151501A AU2001261515A1 AU 2001261515 A1 AU2001261515 A1 AU 2001261515A1 AU 2001261515 A AU2001261515 A AU 2001261515A AU 6151501 A AU6151501 A AU 6151501A AU 2001261515 A1 AU2001261515 A1 AU 2001261515A1
Authority
AU
Australia
Prior art keywords
hpv
gene
cell
promoter
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001261515A
Other languages
English (en)
Inventor
Joel Palefsky
Neerja Sethi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of AU2001261515A1 publication Critical patent/AU2001261515A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001261515A 2000-05-12 2001-05-11 Treatment of human papillomavirus (hpv)-infected cells Abandoned AU2001261515A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20370900P 2000-05-12 2000-05-12
US60203709 2000-05-12
PCT/US2001/015407 WO2001087350A2 (fr) 2000-05-12 2001-05-11 Traitement de cellules infectees par le papillomavirus humain (hpv)

Publications (1)

Publication Number Publication Date
AU2001261515A1 true AU2001261515A1 (en) 2001-11-26

Family

ID=22754994

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001261515A Abandoned AU2001261515A1 (en) 2000-05-12 2001-05-11 Treatment of human papillomavirus (hpv)-infected cells

Country Status (6)

Country Link
US (1) US20040214158A1 (fr)
EP (1) EP1282449A2 (fr)
JP (1) JP2004505892A (fr)
AU (1) AU2001261515A1 (fr)
CA (1) CA2408830A1 (fr)
WO (1) WO2001087350A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1756569A (zh) * 2002-12-27 2006-04-05 印屈根治疗学股份有限公司 增生性病损中乳头瘤病毒和致癌原转化细胞的p53治疗
ES2386000T3 (es) * 2003-12-08 2012-08-07 Loma Linda University Métodos para detectar poxvirus.
JP2008528508A (ja) * 2005-01-21 2008-07-31 イントロジェン・セラピューティクス，インコーポレイテッド 標的細胞の治療および予防核酸への持続性の曝露を可能とする局所投与
WO2006098929A1 (fr) * 2005-03-10 2006-09-21 The Research Foundation Of State University Of New York Virus chimerique pour le traitement du cancer
WO2010045659A1 (fr) 2008-10-17 2010-04-22 American Gene Technologies International Inc. Vecteurs lentiviraux sûrs pour une administration ciblée de multiples molécules thérapeutiques
WO2013177228A1 (fr) 2012-05-22 2013-11-28 Loma Linda University Génération de cellules souches induites par intégration sans transgène
EP2950825B1 (fr) * 2013-02-01 2019-09-11 Genisphere, LLC Complexes adn-dendrimères fonctionnalisés utilisables en vue de la délivrance de gènes en direction de cellules
JP6890831B2 (ja) 2015-07-08 2021-06-18 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖ予備免疫化および免疫療法
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
IL310925A (en) 2016-01-15 2024-04-01 American Gene Tech Int Inc Methods and preparations for activating GAMMA-DELTA T cells
US10888613B2 (en) 2016-02-08 2021-01-12 American Gene Technologies International Inc. Method of producing cells resistant to HIV infection
WO2017156311A2 (fr) 2016-03-09 2017-09-14 American Gene Technologies International Inc. Vecteurs de combinaison et méthodes de traitement du cancer
JP7173548B2 (ja) * 2016-06-08 2022-11-16 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド 非組み込みウイルス送達系およびその関連方法
CA3028982A1 (fr) 2016-07-08 2018-01-11 American Gene Technologies International Inc. Pre-immunisation et immunotherapie du vih
JP7176756B2 (ja) 2016-07-21 2022-11-22 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド パーキンソン病を処置するためのウイルスベクター
KR20190136048A (ko) 2017-04-03 2019-12-09 아메리칸 진 테크놀로지스 인터내셔널 인코포레이티드 페닐케톤뇨증을 치료하기 위한 조성물 및 방법
WO2021195494A2 (fr) * 2020-03-26 2021-09-30 Asklepios Biopharmaceutical, Inc. Promoteur inductible pour la production de vecteurs viraux
WO2023196884A1 (fr) 2022-04-06 2023-10-12 Juno Therapeutics, Inc. Dosage pour la détection du papillomavirus humain (vph) de type 16 (hpv-16)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
GB9621091D0 (en) * 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
ATE327259T1 (de) * 1997-08-05 2006-06-15 Stressgen Biotechnologies Corp Immunantwort gegen hpv antigene hervorgerufen von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einem expressionsvektor fähig zur expression dieser proteine
CA2300957A1 (fr) * 1997-08-15 1999-02-25 Rubicon Laboratory, Inc. Retrovirus et vecteurs viraux
DE19751587A1 (de) * 1997-11-21 1999-07-29 Hoechst Marion Roussel De Gmbh Onkogen- oder virusgesteuerte Expressionssysteme

Also Published As

Publication number Publication date
US20040214158A1 (en) 2004-10-28
CA2408830A1 (fr) 2001-11-22
EP1282449A2 (fr) 2003-02-12
WO2001087350A3 (fr) 2002-11-21
JP2004505892A (ja) 2004-02-26
WO2001087350A2 (fr) 2001-11-22

Similar Documents

Publication Publication Date Title
US20040214158A1 (en) Treatment of human papillomavirus (hpv)-infected cells
US20220154188A1 (en) Compositions and methods for in vivo excision of hiv-1 proviral dna
Boya et al. Viral and bacterial proteins regulating apoptosis at the mitochondrial level
CN107949424B (zh) Tat诱导的基于crispr/核酸内切酶的基因编辑
JP6375273B2 (ja) 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体
Gabuzda et al. Regulation of the visna virus long terminal repeat in macrophages involves cellular factors that bind sequences containing AP-1 sites
Tan et al. In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes
Berthoux et al. Mutations in the N-terminal domain of human immunodeficiency virus type 1 nucleocapsid protein affect virion core structure and proviral DNA synthesis
CN108603196A (zh) Rna向导的对人类jc病毒和其他多瘤病毒的根除
US20020098547A1 (en) JeT promoter
AU2014241622A1 (en) Systems and methods for the targeted production of a therapeutic protein within a target cell
WO2011066578A1 (fr) Vecteurs lentiviraux surs pour administration ciblee de multiple molecules therapeutiques pour traiter le cancer du foie
JP2020503390A (ja) 治療用タンパク質の標的細胞特異的な産生のため、および標的細胞に関連する疾患、状態、または障害の治療のための、膜融合性脂質ナノ粒子、ならびにその作製および使用のための方法
US20220106608A1 (en) Fusogenic lipid nanoparticles for the target cell-specific production of rapamycin inducible therapeutic proteins
Vargas Jr et al. Conditionally replicating lentiviral-hybrid episomal vectors for suicide gene therapy
Graham et al. Human tumor growth is inhibited by a vaccinia virus carrying the E2 gene of bovine papillomavirus
Inouye et al. Potent inhibition of human immunodeficiency virus type 1 in primary T cells and alveolar macrophages by a combination anti-Rev strategy delivered in an adeno-associated virus vector
WO2022247817A1 (fr) Composition nano-pharmaceutique d'acide nucléique-polypeptide destinée au traitement et à la prévention d'une infection par le papillomavirus humain
US20230391836A1 (en) Amino acid sequence that can destroy cells, and related nucleotide sequence and related uses thereof
Sethi et al. Treatment of human papillomavirus (HPV) type 16-infected cells using herpes simplex virus type 1 thymidine kinase-mediated gene therapy transcriptionally regulated by the HPV E2 protein
Lung et al. The use of a human papillomavirus 18 promoter for tissue-specific expression in cervical carcinoma cells
US7423138B2 (en) Compositions and methods for treating papillomavirus-infected cells
Saunders et al. p73 modulates HIV-1 Tat transcriptional and apoptotic activities in human astrocytes
Sharma et al. Addition of a single E2 binding site to the human papillomavirus (HPV) type 16 long control region enhances killing of HPV positive cells via HPV E2 protein-regulated herpes simplex virus type 1 thymidine kinase-mediated suicide gene therapy
US6605281B1 (en) Human papillomavirus vectors for the episomal transduction of host cells and method of making same